<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757506</url>
  </required_header>
  <id_info>
    <org_study_id>A02-B12-11B</org_study_id>
    <nct_id>NCT04757506</nct_id>
  </id_info>
  <brief_title>An Investigation of the Effects of Opioid Receptor Blockade on Changes in Self-esteem and Social Attention</brief_title>
  <official_title>An Investigation of the Effects of Opioid Receptor Blockade on Changes in Self-esteem and Attentional Bias Toward Social Cues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the effects of endogenous opioids on self-esteem and&#xD;
      attentional bias toward social cues. This is achieved by administering the drug naltrexone,&#xD;
      which temporarily decreases endogenous opioid activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2012</start_date>
  <completion_date type="Actual">March 15, 2013</completion_date>
  <primary_completion_date type="Actual">March 15, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-esteem</measure>
    <time_frame>Approximately 2 hours post placebo/drug administration</time_frame>
    <description>Self-reported levels of self-esteem assessed using the Rosenberg Self-Esteem Scale (Rosenberg, 1965). Possible scores range from 1 to 4. Higher scores indicate higher levels of self-esteem.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attentional bias scores for positive social cues on visual probe task</measure>
    <time_frame>Approximately 2 hours post placebo/drug administration</time_frame>
    <description>Attentional bias was assessed using a Visual Probe Task. The investigators used a version of the VPT (DeWall, Maner, &amp; Rouby, 2009) designed to assess attentional bias to cues of social acceptance (i.e., smiles). The outcome measure was attentional bias scores, calculated by subtracting mean reaction time scores on &quot;valid&quot; trials from mean reaction time on &quot;invalid&quot; trials. Higher positive scores indicate greater attentional bias to accepting faces.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Attentional bias scores for negative social cues on visual probe task</measure>
    <time_frame>Approximately 2 hours post placebo/drug administration</time_frame>
    <description>Attentional bias was assessed using a Visual Probe Task. The investigators used a version of the VPT (DeWall, Maner, &amp; Rouby, 2009) designed to assess attentional bias to cues of social rejection (i.e., disapproving faces). The outcome measure was attentional bias scores, calculated by subtracting mean reaction time scores on &quot;valid&quot; trials from mean reaction time on &quot;invalid&quot; trials. Higher positive scores indicate greater attentional bias to disapproving faces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reaction times on neutral-neutral trials on visual probe task</measure>
    <time_frame>Approximately 2 hours post placebo/drug administration</time_frame>
    <description>Reaction times on neutral-neutral trials on the visual probe task were used to assess potential psychomotor side-effects of naltrexone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-liking</measure>
    <time_frame>Approximately 2 hours post placebo/drug administration</time_frame>
    <description>For exploratory purposes, the self-esteem measure (Rosenberg, 1965) was split into two separate subscales examining feelings of self-liking and self-competence as in Tafarodi &amp; Milne, 2002. Self-liking is thought to be more relationally derived and based on internalized perceptions of social approval. Scores range from 1 to 4, with higher scores indicating higher levels of self-liking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-competence</measure>
    <time_frame>Approximately 2 hours post placebo/drug administration</time_frame>
    <description>For exploratory purposes, the self-esteem measure (Rosenberg, 1965) was split into two separate subscales examining feelings of self-liking and self-competence as in Tafarodi &amp; Milne, 2002. Self-competence is thought to be more autonomously derived and based on past goal pursuit. Scores range from 1 to 4, with higher scores indicating higher levels of self-competence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Self Esteem</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>cellulose-filled capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 50 mg oral dose naltrexone (capsule)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>opioid receptor antagonist</description>
    <arm_group_label>Naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  good physical health,&#xD;
&#xD;
          -  normal kidney and liver function results from within previous year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to naltrexone&#xD;
&#xD;
          -  kidney or liver injury or disorder&#xD;
&#xD;
          -  bipolar, panic, or psychotic disorders&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  smoking more than 15 cigarettes per day&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  substance abuse&#xD;
&#xD;
          -  use of opioid analgesics, cocaine, recreational drugs (e.g., marijuana, LSD, ecstasy,&#xD;
             etc.), or prescription medication (except oral contraceptives) within the past 10 days&#xD;
&#xD;
          -  use of over-the-counter drugs (e.g., analgesics, anti-inflammatories, sleeping aids,&#xD;
             etc.) or alcohol within the past 24 hours&#xD;
&#xD;
          -  current experience of pain (e.g., headache)&#xD;
&#xD;
          -  use of anti-diarrheal medications in the 7 days prior to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Bartz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Jennifer Bartz</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available via OSF upon publication of the paper.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT04757506/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

